阿司匹林联合阿伐他汀用于短暂性脑缺血的临床疗效分析

Clinical Therapeutic Effect of the Combination of Aspirin and Atorvastatin for the Treatment of Transient Ischemic Attack

目的:观察分析阿司匹林与阿伐他汀联用治疗短暂性脑缺血的临床疗效。方法:随机选取于2013年8月-2015年5月来我院就诊的短暂性脑缺血患者70例,随机分为观察组(37例)和对照组(33例),两组患者均给予包括维生素C、低分子质量肝素等常规治疗,同时观察组患者给予阿司匹林(100 mg)和阿伐他汀(20 mg)联合用药,口服,一日1次。对照组仅给予阿司匹林(100 mg)进行治疗,口服,一日1次。两组患者的治疗周期均为30天,观察比较两组患者的临床疗效,血液流变学指标(全血粘度、血细胞比容、血浆粘度),神经功能恢复状况及不良反应发生状况,并随访6个月。结果:治疗结束后,观察组患者的总体有效率(94.59%)显著高于对照组患者(72.73%),差异具有统计学意义(P<0.05),两组患者的血液流变学指标均较治疗前降低,且观察组患者的血液流变学指标降低情况显著高于对照组患者(P<0.05),两组患者治疗期间总体不良反应发生率均较低,随访中,治疗组患者的复发率显著低于对照组患者(5.88%vs 25.88%)。结论:阿伐他汀联合阿司匹林治疗短暂性脑缺血治疗效果更显著,且安全性较好。

Objective： To observe and analyze the clinical therapeutic effect of Aspirin combined with Atorvastatin for the treatment of Transient Ischemic Attack （TIA）. Methods： Totally 70 patients with TIA during August 2013 to May 2015 in our hospital were randomly divided into model group （n=37） and control group （n=33）. Both of the two group were given routine treatment including Vitamin C and low molecular weight heparin. Based on these, the patients of control group were given Aspirin （20 mg）, p.o., once a day, and the patients in model group were given Aspirin （100 mg） and Atorvastatin （100 mg）, p.o. once a day. The course of the two groups was 30 d. The therapeutic effect, hemorheological index （Whole blood viscosity, Plasma viscosity, Haematocrit ）, recovery of nervous function and adverse reaction were observed and compared between the two group. Results： The total therapeutic effect of model group was 94.59 %, significantly higher than that of control group （72.73 %） after the treatment （P〈0.05）, the hemorheological indexes of the two groups were low and they were significantly lower in model group than those of control groups （P〈0.05）, and the adverse reaction of the two groups were low. The recurrence rate in the model group was lower than that of the control group （5.88 % vs 25.88 %）. Conclusions： The combination of Aspirin and Atorvastatin for the treatment of TIA have obvious therapeutic efficacy with good safety.